Natus Medical believes its innovative product pipeline and increasing demand for Peloton (newborn hearing screening tests), NicView (provides streaming video for families and babies in the neonatal intensive care unit (NICU) 24/7), and Global Neurodiagnostic (GND) services will help it to achieve the targets for full-year 2016. Natus Medical expects earnings to be in the range of 35−36 cents on the back of revenues of $92−$93 million ($91.9 million reported in the year-ago quarter) for the second quarter of 2016.įor full-year 2016, earnings are projected to be in the range of $1.61−$1.65 per share with revenues in the band of $378−$382 million (up 1.1% at mid-point). The company repurchased $9.1 million of its stock during the quarter. ![]() Meanwhile, Natus Medical reported earnings of 34 cents per share in first-quarter 2016 which beat the Zacks Consensus Estimate by 4 cents and increased 9.7% from the year-ago quarter. This will definitely boost the bottom line in the upcoming quarters. The improving liquidity will help the company to easily fund the acquisition of the additional shares. Natus Medical expects to generate cash flow from operations of almost $70 million, while free cash flow is projected at around $65 million for full-year 2016. As of Mar 31, 2016, the company had cash and cash equivalents of approximately $81 million and an existing line of credit of $25 million. Per management at Natus Medical, the repurchase will be funded by using cash on hand, cash generated from operations, existing credit facilities or other financing options. Share price increased only 0.6% to close at $34.16 on Jun 3, 2016. However, shares did not show much positive movement in response to the news. ( BABY) recently announced an expansion of its share repurchase program, which authorizes it to buy back additional shares worth $20 million by Jun 1, 2017.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |